Pharmaceutical
Technology
Health

Repligen

$58.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.85 (-4.61%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Repligen and other stocks, options, ETFs, and crypto commission-free!

About

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). Read More The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Employees
548
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
2.59B
Price-Earnings Ratio
162.82
Dividend Yield
0.00
Average Volume
367.83K
High Today
$61.51
Low Today
$58.91
Open Price
$61.12
Volume
173.71K
52 Week High
$70.50
52 Week Low
$34.05

Collections

Pharmaceutical
Technology
Health
Biotechnology
US
North America

News

TradingNewsNowMar 22

Present Valuation: Repligen Corporation (NASDAQ: RGEN)

Repligen Corporation trades as part of the healthcare sector and is in the biotechnology industry. The company CEO is Tony J. Hunt. Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Previous Intraday Trading Performance: The RGEN stock showed a previous change of 3.83% with an open at 59.20 and a close of 61.76. It reached an ...

2
Yahoo FinanceMar 12

What Should Investors Know About Repligen Corporation’s (NASDAQ:RGEN) Future?

The most recent earnings update Repligen Corporation’s (NASDAQ:RGEN) released in December 2018 indicated that the company experienced a substantial headwind with earnings declining by -41%. Below, I’ve laid out key growth figures on how market analysts predict Repligen’s earnings growth trajectory over the next couple of years and whether the future looks brighter.

18
MarketBeatMar 8

Stock Price, News, & Analysis for Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide.

2

Earnings

$0.11
$0.14
$0.18
$0.21
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.